Neal Gordon Simon
Fondateur chez Azevan Pharmaceuticals, Inc.
Profil
Dr. Neal G.
Simon is a Chief Executive Officer & Director at Azevan Pharmaceuticals, Inc. He is on the Board of Directors at Azevan Pharmaceuticals, Inc. Dr. Simon was previously employed as a Research Professor by University of Strasbourg and a Chairman-Biological Sciences Division by Lehigh University.
He received his undergraduate degree from State University of New York at Binghamton, a graduate degree from Rutgers State University of New Jersey and a doctorate degree from Rutgers State University of New Jersey.
Postes actifs de Neal Gordon Simon
| Sociétés | Poste | Début |
|---|---|---|
Azevan Pharmaceuticals, Inc.
 Azevan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem. | Fondateur | 01/01/1999 |
Anciens postes connus de Neal Gordon Simon
| Sociétés | Poste | Fin |
|---|---|---|
| University of Strasbourg | Corporate Officer/Principal | - |
| Lehigh University | Corporate Officer/Principal | - |
Formation de Neal Gordon Simon
| Rutgers State University of New Jersey | Doctorate Degree |
| State University of New York at Binghamton | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Azevan Pharmaceuticals, Inc.
Azevan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem. | Health Technology |
